

**Table S2. The median OS, PFS, DCR, ORR in the TACE cohort and the TACE-Sorafenib cohort**

	<b>TACE cohort</b>	<b>T-S cohort</b>	<b>HR* (95%CI)</b>	<b><i>p</i> value</b>
Median OS (m)	10.1 (6.5-13.7)	22.8 (18.8-26.9)	0.454 (0.299-0.688)	<0.001
Median PFS (m)	8.4 (3.0-13.8)	8.6 (2.9-14.2)	1.089 (0.711-1.668)	0.695
DCR (%)	85.1	93.6	-	-
ORR (%)	55.4	70.2	-	-

T-S, TACE-Sorafenib; OS, overall survival; PFS, progression-free survival; DCR, disease control rate; ORR, objective response rate; HR\*, TACE-Sorafenib cohort vs. TACE cohort.